Duration:12 months Quantity: aflibercept 2.0mg/0.05mL Trimonthly injection

2 trials

Sponsors

Department of Ophthalmology, Shiga University of Medical Science

Conditions

age-related macular degenerationretinal vein occlusion

Unknown Phase

Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for age-related macular degeneration

Active, not recruitingJPRN-UMIN000019028

Department of Ophthalmology, Shiga University of Medical Scienceage-related macular degeneration

Start: 2015-09-17Target: 40Updated: 2026-06-29

Evaluation of the efficacy and safety of trimonthly intravitreal injection of aflibercept for retinal vein occlusion

Active, not recruitingJPRN-UMIN000020403

Department of Ophthalmology, Shiga University of Medical Scienceretinal vein occlusion

Start: 2016-01-04Target: 40Updated: 2026-06-29